ÂÜÀòÂÒÂ×

Emily Piccione currently serves as the Director of Translational Research at Inhibrx, Inc., a position held since November 2022. Prior experience includes a role as Principal Scientist in Oncology Biomarker Development at Genentech from August 2019 to November 2022 and Senior Scientist II at Corvus Pharmaceuticals, where responsibilities involved leading cross-functional project teams and overseeing IND-enabling studies for therapeutic antibody programs. Earlier academic experience includes serving as a Postdoctoral Fellow and Senior Scientist at Stanford University School of Medicine, focusing on bispecific antibody development for blood cancers and conducting research that led to a Ph.D. in Cancer Biology from Stanford University School of Medicine. Educational credentials also include a B.S. in Biology from The College of New Jersey.